Autolus Therapeutics (AUTL) Net Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Net Cash Flow data on file, last reported at $17.4 million in Q4 2025.

• Quarterly Net Cash Flow rose 104.45% year-over-year to $17.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$129.4 million (down 1048.72% YoY) and the FY2025 annual result came in at -$129.4 million, down 1048.72% from the prior year.
• Net Cash Flow advanced to $17.4 million in Q4 2025, from -$34.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $520.4 million in Q1 2024 to a low of -$391.5 million in Q4 2024.
• A 5-year average of -$2.0 million and a median of -$35.0 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 1213.57% in 2024, down 1389.39% in 2024.
• Tracing AUTL's Net Cash Flow over 5 years: stood at $136.7 million in 2021, then soared by 52.42% to $208.3 million in 2022, then slumped by 112.62% to -$26.3 million in 2023, then slumped by 1389.39% to -$391.5 million in 2024, then jumped by 104.45% to $17.4 million in 2025.
• The last three Net Cash Flow figures came in at $17.4 million (Q4 2025), -$34.1 million (Q3 2025), and $22.4 million (Q2 2025), per Business Quant data.